7-Dehydrocholesterol is an endogenous suppressor of ferroptosis

Florencio Porto Freitas1, Hamed Alborzinia2,3, Ancély Ferreira Dos Santos1

  • 1Rudolf Virchow Center for Integrative and Translational Bioimaging, University of Würzburg, Würzburg, Germany.

Nature
|January 31, 2024
PubMed

Insights

Cancer cells exploit 7-dehydrocholesterol (7-DHC) for survival, not death. This molecule shields lipids from oxidation, promoting a ferroptosis-resistant state and aggressive tumor growth.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Cancer Research

Background:

  • Ferroptosis is a regulated cell death pathway crucial in cancer therapy.
  • Tumors adapt metabolically to resist ferroptosis and promote survival.
  • 7-dehydrocholesterol reductase (DHCR7) and its substrate 7-dehydrocholesterol (7-DHC) roles in cancer are not fully understood.

Purpose of the Study:

  • To investigate the role of DHCR7 and 7-DHC in ferroptosis.
  • To elucidate the function of 7-DHC accumulation in cancer cells.
  • To determine the impact of 7-DHC on tumor resistance to ferroptosis.

Main Methods:

  • Investigated proferroptotic activity of DHCR7.
  • Analyzed the prosurvival function of 7-DHC in cancer cells.
  • Validated findings in neuroblastoma and Burkitt's lymphoma xenograft models.

Main Results:

  • DHCR7 exhibits proferroptotic activity.
  • Accumulation of 7-DHC confers a prosurvival function in cancer cells.
  • 7-DHC shields lipids from peroxidation, inducing ferroptosis resistance and a more aggressive tumor phenotype.

Conclusions:

  • 7-DHC possesses significant antiferroptotic activity.
  • Cancer cells utilize 7-DHC as an intrinsic mechanism to escape ferroptosis.
  • Targeting 7-DHC metabolism could be a novel cancer therapeutic strategy.